PORTFOLIO NEWS NGM Bio Outlines 2022 Strategic Priorities Across Its Portfolio of Clinical-Stage Oncology, Retinal and Liver and Metabolic Programs January 10, 2022 Read More » Tenaya Therapeutics Provides 2022 Business Updates January 10, 2022 Read More » Surrozen Announces Key 2022 Milestones for Lead Programs and Acceleration of Research Pipeline January 10, 2022 Read More » ORIC Pharmaceuticals Provides Corporate Update and Highlights Key Upcoming Milestones January 10, 2022 Read More » Nurix Therapeutics Advances Clinical and Preclinical Pipeline and Outlines 2022 Catalysts January 10, 2022 Read More » Eikon Therapeutics Announces $517.8 Million Series B Raise and Expansion of Executive Leadership Team January 6, 2022 Read More » Escient Pharmaceuticals Appoints Joshua Grass, MBA As CEO January 5, 2022 Read More » Synthekine Announces Publication of Preclinical Data Demonstrating In Vivo Control of CD19 CAR-T Cells with its Orthogonal IL-2 System December 23, 2021 Read More » Remix Therapeutics Appoints Zaven Kaprielian, Ph.D., as Chief Scientific Officer December 15, 2021 Read More » Neurona Therapeutics Announces C-Suite Leadership Team December 13, 2021 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Page16 Page17 Page18 Page19 Page20 Next »
NGM Bio Outlines 2022 Strategic Priorities Across Its Portfolio of Clinical-Stage Oncology, Retinal and Liver and Metabolic Programs January 10, 2022 Read More »
Surrozen Announces Key 2022 Milestones for Lead Programs and Acceleration of Research Pipeline January 10, 2022 Read More »
ORIC Pharmaceuticals Provides Corporate Update and Highlights Key Upcoming Milestones January 10, 2022 Read More »
Nurix Therapeutics Advances Clinical and Preclinical Pipeline and Outlines 2022 Catalysts January 10, 2022 Read More »
Eikon Therapeutics Announces $517.8 Million Series B Raise and Expansion of Executive Leadership Team January 6, 2022 Read More »
Synthekine Announces Publication of Preclinical Data Demonstrating In Vivo Control of CD19 CAR-T Cells with its Orthogonal IL-2 System December 23, 2021 Read More »
Remix Therapeutics Appoints Zaven Kaprielian, Ph.D., as Chief Scientific Officer December 15, 2021 Read More »
